Aurobindo Pharma Ltd. NSE: AUROPHARMA | BSE: 524804

Falling Comet

Download real time

1123.20 3.00 (0.27%)

29.45% Fall from 52W High

1.2M

NSE+BSE Volume

NSE 26 Jun, 2025 3:31 PM (IST)

Regulatory Approval

Aurobindo Pharma's arm receives approval from the UK’s MHRA to market Dyrupeg See details

Aurobindo Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Aurobindo Pharma Ltd. from all sources in a single place.

Load latest

Aurobindo Pharma Ltd.

11 Sep 2024

1123.20

0.27%

Company Update

AUROBINDO PHARMA LTD. - 524804 - New Injectable Facility Of Eugia Steriles Private Limited, A 100% …

BSE India

Intimation of receipt of first product approval from USFDA for Eugia Steriles Private Limited, a 100% stepdown subsidiary.

Aurobindo Pharma Ltd.

02 Sep 2024

1123.20

0.27%

Aurobindo Pharma to step up focus on biosimilars, lines up a slew of products

Business Line

Plans to set up exclusive manufacturing facility with an annual capacity of 25-30 million vials

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Aurobindo Pharma Ltd.

30 Aug 2024

1123.20

0.27%

AGM

AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BSE India

Submission of Voting Results of 37th Annual General Meeting of the company held on August 29, 2024

Aurobindo Pharma Ltd.

29 Aug 2024

1123.20

0.27%

AGM

AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Outcome of AGM

BSE India

Submission of proceedings of 37th Annual General meeting of the Company held on August 29, 2024.

Aurobindo Pharma Ltd.

29 Aug 2024

1123.20

0.27%

Company Update

AUROBINDO PHARMA LTD. - 524804 - The Company Has Received An Order From The Deputy Commissioner, …

BSE India

The Company has received an order from the Deputy Commissioner, Punjagautta(ST) STU-1 of GST, Hyderabad.

Aurobindo Pharma Ltd.

28 Aug 2024

1123.20

0.27%

Company Update

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Investor meet

Aurobindo Pharma Ltd.

27 Aug 2024

1123.20

0.27%

Corp. Note

AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

Intimation of loss of share certificates.

Aurobindo Pharma Ltd.

26 Aug 2024, 07:57PM

1123.20

0.27%

Aurobindo, others recall products in US market over production issue: USFDA

Business Standard

Drug makers Aurobindo Pharma, Glenmark and FDC are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Aurobindo Pharma USA Inc -- a unit of Hyderabad-based drug major -- is recalling 240 bottles of pain-relieving medication Healthy Living Acetaminophen, Aspirin (NSAID) and caffeine tablets. As per the latest enforcement report of USFDA, the company is recalling the affected lot due to "Missing Label". Some bottles are missing the manufacturer's label that includes the drug facts information, the US health regulator said. The New Jersey-based Aurobindo Pharma USA Inc initiated the Class 1 recall on July 11, it said. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, produced at a Madhya Pradesh plant, due to "Failed Dissolutio

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

26 Aug 2024, 01:31PM

1123.20

0.27%

Company Update

AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Closure of Buy Back

BSE India

Submission of Certificate of Extinguishments 51,36,986 equity shares of Re. 1 each bought back under the Company''s Buyback offer.

Aurobindo Pharma Ltd.

25 Aug 2024, 02:00PM

1123.20

0.27%

Aurobindo Pharma Arm Pulled By US Drug Regulator Over Manufacturing Lapses, Data Inaccuracy

NDTV Profit

USFDA had inspected the Hyderabad-based plant of Eugia Pharma Specialities from Jan. 22 to Feb. 2, 2024.

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

USFDA pulls up Eugia for manufacturing lapses at its Telangana plant

Business Standard | 25 Aug 2024, 02:00PM

Is Aurobindo Pharma Ltd. worth buying?

1247 Votes:

Buy 80.19%

Sell 13.79%

Hold 6.01%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >